Core Viewpoint - The announcement indicates that the clinical trial for the innovative drug CKBA ointment, developed by the subsidiary Bochuangyuan of TianKang (301263), has shown positive efficacy and safety in treating non-segmental vitiligo, supporting the continuation to Phase III trials [1] Group 1: Clinical Trial Results - The Phase II clinical trial data for CKBA ointment has been organized and unblinded, revealing promising results [1] - In the high-dose group (1.5% BID), the proportion of subjects achieving F-VASI50 and F-VASI25 scores was better than that of the placebo group, with 36% (18 out of 50) showing improvement and varying degrees of repigmentation [1] - The main adverse events reported were mild itching and erythema, classified as grade 1-2, with no serious adverse events occurring during the trial [1]
泰恩康：CKBA软膏白癜风适应症II期临床试验初步结果达到预期目标